And yet, ask most HCPs whether their experience of engaging with pharma has meaningfully improved, and the answer is usually ...

An AI-designed vaccine against all variants of the coronavirus SARS-CoV-2 – designed using an AI-powered platform developed ...

Parabilis Medicines has revealed the financial details behind its recently announced IPO, hoping to raise up to $475 million ...

Sanofi's consumer healthcare unit Opella could finally be on course to bring an over-the-counter PDE-5 inhibitor for erectile dysfunction to the US market, after the FDA relaxed its clinical hold on a ...

A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma group to develop an ...

Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...

In a sit-down interview with pharmaphorum, Henar Hevia, EMEA therapeutic lead for oncology and Carolyn Sousa, EMEA strategy ...

The London company, based at the King's Cross life sciences and tech hub and led by former scientists at AstraZeneca, ...

New trial data with Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran have ...

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

A closely-watched lawsuit in the US Supreme Court has reached its conclusion, and sets an important precedent in the battle between brand owners and generic drugmakers over 'skinny' labels for ...

AbbVie's antibody-drug conjugate (ADC) Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, with hundreds of women every year expected to be eligible for ...